Assesmentof Fibro Q test, AAR & APRI indices as markers of fibrosis in chronic liver disease


Original Article

Author Details : Shilpa A, Ambresh Ayyali*

Volume : 7, Issue : 1, Year : 2021

Article Page : 39-43

https://doi.org/10.18231/j.ijn.2021.007



Suggest article by email

Get Permission

Abstract

Introduction : Chronic liver disease can vary from mild hepatic inflammation without fibrosis to advanced hepatic fibrosis and cirrhosis. The use of ultrasound for the confirmation of complications during biopsy procedures increases the cost of treatment and may also increase the duration of hospitalization. Fibro Q test (FQT), Aspartate amino transferase – Alanine amino transferase ratio (AAR) & Aspartate amino transferase- platelet ratio index (APRI) are the three non-invasive and simple indices proposed for assessing fibrosis in CLD.
Objectives: To know the efficacy of the indices- Fibro Q test, AAR, APRI as markers of Fibrosis in CLD. To know which among these indices would be the high sensitive marker of liver fibrosis.
Materials and Methods: This study includes 60 subjects, out of which 30 were clinically diagnosed as CLD and were confirmed by abdominal ultrasound and 30 were age matched healthy controls.
Results: Fibro Q, AAR & APRI were significantly increased in cases compared to controls. The increase in Fibro Q test in cases was highly significant (p-0.0001) when compared to controls.
Conclusion: Fibro Q test, AAR & APRIindicesare efficient markers to evaluate liver fibrosis in CLD patients. Fibro Q, a novel non-invasive test, is highly sensitive marker than AAR & APRI.

Keywords: Fibro Q Test, Alanine amino transferase ratio (AAR), Aspartate amino transferase platelet ratio index (APRI), Chronic liver Disease.


How to cite : Shilpa A, Ayyali A , Assesmentof Fibro Q test, AAR & APRI indices as markers of fibrosis in chronic liver disease. IP Indian J Neurosci 2021;7(1):39-43


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.







Article History

Received : 14-01-2021

Accepted : 12-02-2021


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijn.2021.007


Article Metrics






Article Access statistics

Viewed: 1332

PDF Downloaded: 576



Medical Abbreviation List